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ABSTRACT
Polycystic ovary syndrome (PCOS) affects
6–10% of women and could be considered one
of the most common endocrine alterations in
women of reproductive age. The syndrome is
characterized by several hormonal and meta-
bolic alterations, including insulin resistance
and hyperandrogenism, which play a severe
detrimental role in the patient’s fertility. We
aimed to offer an overview about drug meta-
bolism in the PCOS population. Nevertheless,
we did not find any study that directly com-
pared drug metabolism between PCOS and
healthy women. We therefore decided to sum-
marize briefly how hormonal and insulin sen-
sitizer drugs act differently in healthy and PCOS
women, who show altered steroidogenesis by
theca cells and metabolic imbalance, focusing
especially on assisted reproductive techniques.
To date, data about drug metabolism in the
PCOS population appears to be extremely
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limited. This important gap could have signifi-
cant implications for therapeutic approaches
and future perspectives: the dosage of drugs
commonly used for the treatment of PCOS
women should be tailored according to each
patient’s characteristics; we should implement
new clinical trials in order to identify the best
pharmacologic strategy for PCOS patients
undergoing in vitro fertilization (IVF); it would
be advisable to create an international expert
panel to investigate the drug metabolism in the
PCOS population.
Keywords: Assisted reproductive technology;
Fertility; Hyperandrogenism; Hyperinsuline-
mia; Infertility; Insulin resistance; Insulin
sensitizers; In vitro fertilization; Oligo-
anovulation; Polycystic ovary syndrome
INTRODUCTION
Polycystic ovary syndrome (PCOS) affects 6–10%
of women [1] and could be considered one of the
most common endocrine alterations in women
of reproductive age. This syndrome is character-
ized by clinical or biochemical hyperandro-
genism, oligo-anovulatory cycles and polycystic
ovaries. According to the Rotterdam criteria, it is
necessary to have two of the three aforemen-
tioned criteria to diagnose PCOS [2]. On the other
hand, 10 years ago the Androgen Excess-PCOS
(AE-PCOS) Society Task Force stressed the
importance of hyperandrogenism in PCOS pre-
sentation [3], and 3 years later confirmed the
presence of hyperandrogenism together with
ovarian dysfunction (oligo-anovulation and/or
polycystic features) as diagnostic criteria,
notwithstanding the necessity of accurate dif-
ferential diagnosis for other disorders [1].
The exact pathogenetic mechanisms behind
different PCOS features are still unclear; how-
ever, numerous studies have deepened our
understanding, and the causes are linked to
steroidogenesis enzyme function and metabolic
disturbance related to insulin resistance. Con-
sidering these alterations in PCOS women, sev-
eral drugs and other metabolically active
compounds may have different effects in this
population group compared with healthy
women without PCOS as a result of hormonal
and metabolic imbalance. In this literature
review we aim to offer an overview about drug
metabolism in women with PCOS.
After extensive literature review we did not
find any study that evaluated drug metabolism
in PCOS compared with healthy women. For
this reason, we decided to summarize briefly
different pathogenic mechanisms behind PCOS
and how hormonal and insulin sensitizer med-
ications act differently in healthy and PCOS
women, especially with respect to assisted
reproductive techniques.
METHODS
We searched the following electronic biblio-
graphic databases: MEDLINE, EMBASE, Global
Health, The Cochrane Library (Cochrane Data-
base of Systematic Reviews, Cochrane Central
Register of Controlled Trials, Cochrane
Methodology Register), Health Technology
Assessment Database, and Web of Science (sci-
ence and social science citation index). We
included only manuscripts published in the
English language, without time restriction.
Titles and/or abstracts of studies retrieved using
the search strategy and those from additional
sources were screened independently by two
authors (V.L.L.R., S.G.V.) to identify studies that
potentially meet the inclusion criteria outlined
above and fall within the study aims. The full
texts of these potentially eligible studies were
retrieved and independently assessed for eligi-
bility by other two authors (G.V., S.C.). Any
disagreement between them over the eligibility
of particular studies was resolved through dis-
cussion with a third author (M.B.). A standard-
ised, pre-piloted form was used to extract data
from the included studies for assessment of
study quality and evidence synthesis. The sear-
ches were rerun just before the final analyses, in
order to include further studies for inclusion.
On the basis of the aim of the current paper,
we first searched ‘‘polycystic ovary syndrome
AND drug metabolism’’, ‘‘polycystic ovary syn-
drome AND pharmacokinetics’’, ‘‘polycystic
ovary syndrome AND pharmacodynamics’’:
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from this first search, we did not identify any
relevant study comparing directly drug meta-
bolism between PCOS and healthy women.
Subsequently, we searched ‘‘polycystic ovary
syndrome AND substrate’’ and we found 135
items that were not pertinent to our topic; in
addition, searching ‘‘pharmacokinetics OR
pharmacokinetics AND polycystic ovary syn-
drome’’ afforded 173 items, but only one study
pertinent to our topic, a study of pregnant
women affected by PCOS [4]. Surprisingly, we did
not find any study that directly compared drug
metabolism between PCOS and healthy women.
We therefore decided to summarize briefly how
hormonal and insulin sensitizer drugs act differ-
ently in healthy and PCOS women, who show
intrinsic altered steroidogenesis by theca cells
and metabolic imbalance, focusing especially on
assisted reproductive techniques.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
Steroidogenesis Alteration in PCOS
Usually androgens have only been considered as
detrimental hormones in oocyte maturation;
however, recently their in follicle maturation has
been re-evaluated. New evidence showed that
androgen, via genomic and non-genomic signal
transduction, induced oocyte maturation, espe-
cially in the early stage of follicle maturation
[5, 6]. Androgen acts synergistically with follicle-
stimulating hormone (FSH), modifying
steroidogenic enzymes and metabolism in gran-
ulosa cells [6]. To confirm these results, treat-
ment of follicles with anti-androgenic drugs was
shown to alter and arrest oocyte meiotic matu-
ration. Nevertheless, excess androgen has detri-
mental effects on oocyte maturation.
Hyperandrogenism occurs in up to 70–80%
women affected by PCOS and it is extremely
frequent during adolescence. The aetiology of
hyperandrogenism during PCOS is not com-
pletely understood. In normal women, andro-
gens are synthesized by ovarian theca cells and
adrenal glands, contributing half and half to
circulating testosterone during reproductive age
[7]. Interestingly, hyperandrogenism in PCOS
appears to be related to dysregulation of
steroidogenesis in both ovary and adrenal
glands. Luteinising hormone (LH) also plays a
pivotal role in the regulation of ovarian andro-
gen production, whereas adrenocorticotropic
hormone (ACTH) regulates androgen produc-
tion by adrenal glands. In addition, several
enzymes of the cytochrome P450 family are
involved in hormonal balance [8] including
cholesterol side-chain cleavage enzyme (P450
scc), aromatase (P450 arom), 3b-hydroxysteroid
dehydrogenase type II (3bHSD-II) and steroid
acute regulatory protein.
Several studies confirmed the reduction of
aromatase activity in ovaries from hyperandro-
genic PCOS women with respect to normoan-
drogenic ones [9, 10], leading to a significant
reduction of oestradiol/testosterone ratio.
Interestingly, aromatase activity is enhanced by
oestrogens and inhibited by androgens [10].
One study found a reduction of 3bHSD-II
activity in hyperandrogenic PCOS women
compared to normoandrogenic PCOS ones [11].
Other data showed increased 11b-hydroxys-
teroid dehydrogenase II (11b-HSDII) activity to
convert dehydroepiandrosterone (DHEA) into
androstenedione in hyperandrogenic PCOS
women compared to normoandrogenic ones
and controls [9].
Steroidogenesis is overactive at multiple
steps in PCOS, especially concerning 17,20-
lyase activity [12]: indeed, accumulating evi-
dence suggests that androstenedione/17-OH
progesterone ratio in response to gonadotropin-
releasing hormone (GnRH) stimulation is lower
in PCOS women compared with healthy con-
trols, probably as a result of the lower activity of
17a-hydroxylase [13].
Recent data confirmed increased activities of
steroidogenic enzymes in hyperandrogenic
PCOS women, although the regulation of delta
(D)-4 and D-5 enzymes seems different. On the
one hand, the 17a-hydroxylase [14] and 17,20-
lyase [8, 14] activities in the D-4 pathway of
hyperandrogenic PCOS women lead to higher
production rates of 17a-hydroxyprogesterone
from progesterone, and androstenedione from
17a-hydroxyprogesterone, with respect to nor-
moandrogenic PCOS women; on the other hand,
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both hyperandrogenic and normoandrogenic
PCOS women have similar activity of the D-5
pathway [9, 14]. In partial agreement with these
results, others showed that oestrogens may acti-
vate 17,20-lyase, increasing only the production
rate of androstenedione (D-4 pathway) [15], or
both androstenedione and DHEA (D-4 and D-5
pathways) [10], even though not all studies
confirmed this hypothesis [14]. Nevertheless,
after diagnostic criteria standardization, robust
data proved that the phosphorylation of serine/
threonine residues, as well as cytochrome b5 and
cytochrome c allosteric actions were all involved
in 17,20-lyase regulation [16, 17]. Not surpris-
ingly, the dysregulation of the cytochrome P450
17a-hydroxylase (P450c17a) and consequent
increase in 17,20-lyase activities were observed
only in PCOS.
Hyperinsulinemia in PCOS
Hyperinsulinemia plays key role in the patho-
genesis of PCOS and related hyperandrogenism.
In particular, some studies showed a decrease of
insulin sensitivity from 35% to 40% [18, 19].
Despite the typical insulin resistance of PCOS,
previous studies found that ovarian theca cells
had hypersensitivity to insulin stimulation and
increase androgen production in response to it
[20–22]. This point is particularly debated: some
studies showed that insulin alone is able to
stimulate testosterone production by cultured
theca cells from normal and PCOS patients [22];
conversely, others found that insulin alone is
not able to stimulate testosterone production
[20]. Similarly, porcine theca cell culture
showed increased expression of cytochrome
P450 17alpha-hydroxylase/17,20-lyase (CYP17)
after insulin and LH stimulation [23], whereas
others failed to confirm these results [24].
Interestingly, many studies showed that
prolonged suppression of insulin in PCOS
women by weight loss [25], diazoxide [26], sta-
tins or metformin [27–29] results in significant
reduction of androgen production. Diazoxide-
mediated reduction of insulin level was also
found even in lean normoinsulinemic PCOS
women [30], but the same did not occur for
testosterone levels [31].
The elevated LH in PCOS women is able to
stimulate steroidogenesis within theca cells. In
addition, theca cells were shown to be abnor-
mally sensitive to LH stimulation, although
downregulation of LH receptors may occur [32].
Therapeutic Approaches
Assisted Reproductive Techniques
Female infertility has increased in the last dec-
ades: recent data from the Centers for Disease
Control (CDC) National Survey of family
growth show that 6% of women aged between
15 and 44 years of childbearing age are infertile
and 12% have impaired fertility [33]. Aging is
one of the principal factors that play a detri-
mental role in female fertility as a result of
reduced quality of oocytes, ovulatory dysfunc-
tion and other gynaecological disorders [34, 35].
Several cohort studies on large populations
found that oocyte quality and embryo devel-
opment may be severely affected by PCOS [36].
In particular, accumulating evidence suggests
that the number of small preantral follicles is
increased in anovulatory PCOS women: the
excess of these types of follicles may be due to
accelerated follicle growth and/or prolonged
survival (reduced atresia) of small follicles [37].
Interestingly, others found that granulosa cells
from ovulatory PCOS women have similar
response to FSH with respect to healthy women;
conversely, granulosa cells isolated from some
small to medium-sized antral follicles obtained
from anovulatory PCOS women showed
increased oestradiol production in response to
FSH and premature responsiveness to LH
[38, 39]. This process seems to allow overex-
pression of LH receptors and premature lutein-
isation of granulosa cells [40], which could be
considering a leading cause of the arrest of fol-
licular development in anovulatory PCOS
women. Nevertheless, some authors found that
follicles from PCOS women undergoing GnRH
analogue/FSH stimulation for in vitro fertiliza-
tion (IVF) show normal luteinisation [40].
Recently, PCOS phenotypes were further
investigated and this approach has improved
our knowledge about hormonal/metabolic dys-
regulation, especially in ovulatory/
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hyperandrogenic PCOS women and ovulatory/
normoandrogenic ones [38]. According to
recent evidence, hyperandrogenic women with
PCO on ultrasound are at high risk of develop-
ing hyperstimulation syndrome during ovula-
tion induction [41]. In addition, ovulatory
women with PCO did not show worse IVF/in-
tracytoplasmic sperm injection (ICSI) outcomes
(including live birth rate) compared to healthy
controls [42].
Some studies found that PCOS women
undergoing IVF had lower FSH, the oocyte
retrieval was higher and the fertilization rate
slightly lower compared with controls, without
any significant difference regarding embryo
arrest (EA) rate [43], regardless of stimulation
protocol used and testosterone level. Although
others confirmed that there is no difference in
EA, clinical abortion rate in PCOS women seems
to be higher than in healthy controls [44].
To date, it is widely accepted that hyperan-
drogenism, high LH level and insulin resistance
may all play a detrimental role in oocyte quality
[45–47]: these alterations seem to be particu-
larly pronounced in the zona pellucida of
oocytes from PCOS women and this may
account, at least in part, for the lower fertiliza-
tion rate observed during ICSI [48].
However, robust data about this topic are
still lacking and the evidence published so far
does not allow one to draw a firm conclusion
about the best management of hormonal/
metabolic dysregulation in PCOS patients
undergoing IVF. Although a recent meta-anal-
ysis [49] demonstrates similar pregnancy and
live birth rates per cycle (despite an increased
cancellation rate, but more oocytes retrieved
per retrieval and a lower fertilization rate) in
PCOS women undergoing IVF, we truly think
that future pharmacologic strategies for assisted
reproductive technologies should be tailored
according to the patient’s characteristics and,
most importantly, PCOS phenotype.
Insulin Sensitizer Drugs
Recent data suggested that the reduction of
insulin level with diazoxide or insulin sensitizer
drugs such as metformin, thiazolidinediones
(PPAR-c agonist) and inositols also reduces
hyperandrogenism [50–52]. Because insulin
resistance and secondary hyperinsulinemia play
an important role in hyperandrogenism,
anovulation or irregular cycles, and metabolic
alterations in both lean and obese PCOS
patients, insulin sensitizers are currently
receiving increasing attention for pharmaco-
logic management of this syndrome [53]. Met-
formin’s effect appears to be mediated by
reduction of insulin level, both in normal
weight and obese women, improving also
hyperandrogenism [54–57]. Some authors
showed that metformin acts directly on ovarian
steroidogenesis in a dose-dependent manner:
gonadotropin and insulin stimulate proges-
terone and oestradiol production by theca cells,
whereas metformin inhibits androgen produc-
tion with no effect on progesterone [57].
Beside metformin, to date inositols have also
received increasing attention owing to their
safety profile and key role in modulating sec-
ondary messenger activity in insulin signal
transduction pathways [58]. Inositol is a
polyalcohol, it is classified as an insulin sensi-
tizer and it is a secondary messenger in insulin
signalling [58, 59]. We know that two different
stereoisomers are currently used in the treat-
ment of PCOS: myo-inositol (MI) and D-chiro-
inositol (DCI). Both stereoisomers have an
insulin-like action in vivo. In humans, accu-
mulating evidence suggests that MI and DCI
have clear and beneficial effects on oocyte
maturation and metabolic pathways [59, 60].
Confirming the latter role, others found that
DCI levels were about 50% lower in tissue and
urinary samples from patients with type 2 dia-
betes compared to those in healthy controls
[61]. Both MI and DCI were therefore evaluated
in PCOS women and shown to ameliorate hor-
monal and metabolic parameters [62, 63].
Although the last Cochrane systematic review
about the topic does not offer a robust recom-
mendation about the best treatment for PCOS
among insulin sensitizer medications [64], a
recent study did not find any significant differ-
ence between metformin and MI in lowering
body mass index, ameliorating insulin sensitiv-
ity and improving the menstrual cycle [65].
Robust data underline the importance of MI
in oocyte differentiation and the possibility to
improve IVF outcomes in PCOS women [66–68]:
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in particular, the direct correlation between
oocyte quality and follicular fluid concentration
of MI was demonstrated both in animal models
and humans [69, 70]. Unfer et al. compared MI
with DCI in patients with PCOS, finding that MI
had the capacity to ameliorate the quality of
oocytes, to decrease the number of immature
oocytes and to improve the number of good
quality embryos compared to DCI treatment
during an ovarian stimulation protocol [67];
others found that in patients under 35 years
old, MI plus DCI improved the fertilization rate
[68].
Administration of either MI (4 g/day) or DCI
(1 g/day) together with folic acid reduced
androgens, LH level, LH/FSH ratio and insulin
sensitivity in PCOS women [71–73]. MI seems to
have the most marked effect on metabolic
parameters, whereas DCI seems to have the
most marked effect on hyperandrogenism
[74–79]. According to several studies, MI is able
to increase oocyte quality, reducing the rate of
immature oocytes, during IVF [62, 63, 74]. Last
but not least, MI seems able to reduce the days
of FSH stimulation, oestradiol level before
human chorionic gonadotropin administration
and risk of hyperstimulation syndrome [63].
Once again, we take the opportunity to under-
line that future pharmacologic strategies should
target insulin resistance selectively according to
each patient’s characteristics. To date we are
able to measure insulin resistance, for example
using the homeostasis model assessment, so
that we would solicit future tailored treatment
of PCOS women.
To date we have a number of studies on
insulin sensitizer therapies to assess fertility
outcomes in women with PCOS; there were no
significant differences in live birth or fetal out-
comes to recommend their use in routine clin-
ical practice.
New Possible Targets
A recent mathematical review of microarray
data in patients with PCOS showed that 504
genes are differently expressed, accounting for
the altered hormonal/metabolic pathways in
this syndrome [80]. Some authors found that
the level of serological thymidine kinase 1
(STK1), a protein kinase involved in liver
metabolism of metformin, was strictly related to
the ovulation response after treatment with
metformin and, additionally, the response dif-
fers according to PCOS phenotypes [81]. Simi-
larly, other gene expressions may play pivotal
roles in addressing altered drug action(s) during
PCOS [82]. For example, the adipokine che-
merin physiologically binds it receptor, che-
mochine receptor like-1, and inhibits FSH-
induced steroidogenesis; according to recent
evidence from a mouse model, chemerin is able
to suppress FSH-induced progesterone and
oestrogen secretion in preantral follicles and
granulosa cells, also inhibiting aromatase
expression [83]. Another possible strategy could
be to target phosphatidylinositide 3-kinase
(PI3K): indeed, recent data showed that the
flavonoid quercetin may have a beneficial effect
in PCOS by virtue of inhibition of PI3K, which
was attributed to a decrease in the expression of
CYP17A1 gene, and thereby has a key role in
steroidogenesis [84].
CONCLUSIONS
To date, PCOS could be considered as a multi-
factorial disease due to concurrent hormonal
and metabolic alterations that influence each
other. Insulin resistance represents one of the
key elements of the syndrome and causes mul-
tiple effects: on the one hand it increases
androgen production by theca cells, on the
other hand it alters the follicle maturation and
reduces oocyte quality. On the basis of this
scenario, insulin resistance rapidly became an
important target and several trials found bene-
ficial effects of insulin sensitizer drugs on hor-
monal, metabolic and even reproductive
outcomes in the PCOS population. Despite
these important therapeutic improvements, we
should consider that the PCOS population may
have significantly different responses to several
classes of drugs as a result of a unique hor-
monal/metabolic environment. The situation
could be even more complicated if we consider
that PCOS could not be identified as a single
syndrome, but as different phenotypes
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according to clinical and biochemical charac-
teristics. To date, data about drug metabolism in
the PCOS population appears to be almost non-
existent or at least extremely limited. This
important gap in the literature could have sig-
nificant implications for therapeutic approa-
ches and future perspectives: first of all, the
dosage of drugs commonly used for the treat-
ment of PCOS women should be tailored
according to each patient’s characteristics; sec-
ond, we should implement new clinical trials in
order to identify the best pharmacologic strat-
egy for PCOS patients undergoing IVF; finally, it
would be advisable to create an international
expert panel to investigate the drug metabolism
in the PCOS population.
In addition, we take the opportunity to
solicit new research aimed to also explore how
different classes of drugs influence the epige-
netic up- and downregulation of genes related
to steroidogenesis and insulin transduction
signalling, especially through genome-wide
association studies (GWAS).
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